BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34132693)

  • 1. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
    Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience.
    Allen CJ; Blumenthaler AN; Smith GL; Das P; Minsky BD; Blum M; Ajani J; Mansfield PF; Ikoma N; Badgwell BD
    Ann Surg Oncol; 2021 Feb; 28(2):758-765. PubMed ID: 32696305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
    Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 9. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy.
    Chapman WC; Kim H; Bauer P; Makhdoom BA; Trikalinos NA; Pedersen KS; Glasgow SC; Mutch MG; Silviera ML; Roy A; Parikh PJ; Hunt SR
    Dis Colon Rectum; 2022 Feb; 65(2):198-206. PubMed ID: 34990423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy in non-cardia gastric cancer patients--does it improve survival?
    Saedi HS; Mansour-Ghanaei F; Joukar F; Shafaghi A; Shahidsales S; Atrkar-Roushan Z
    Asian Pac J Cancer Prev; 2014; 15(20):8667-71. PubMed ID: 25374187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
    Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O'Connell RL; Verghis J; Willis D; Kron T; Crain M; Murray WK; Lordick F; Swallow C; Darling G; Simes J; Wong R
    Ann Surg Oncol; 2017 Aug; 24(8):2252-2258. PubMed ID: 28337660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer.
    Li R; Hou WH; Chao J; Woo Y; Glaser S; Amini A; Nelson RA; Chen YJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):950-958. PubMed ID: 30099371
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
    Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
    BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    Martin-Romano P; Sola JJ; Diaz-Gonzalez JA; Chopitea A; Iragorri Y; Martínez-Regueira F; Ponz-Sarvise M; Arbea L; Subtil JC; Cano D; Ceniceros L; Legaspi J; Hernandez JL; Rodríguez J
    Br J Cancer; 2016 Sep; 115(6):655-63. PubMed ID: 27537382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.